Why is GLUE down?
Down 5% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%.
- Its Nov 5 results:
−2Long-term trend
Down 5% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%.
−2Long-term trend
GLUE's Quality Score rose 1 point on Fri, Nov 20, to -8. More shares traded than usual.
Follow GLUE's trial news. Pro members can get an alert when Monte Rosa Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Sales down 61% on the year |
| Latest filing | 8-K, Nov 5 |
Tue Dec 1: Piper Sandler 38th Annual…Investor conference · date confirmed.
Expected to report Tue Mar 16, before the open
The company says its cash lasts into 2029 (8-K, Nov 5).
An officer, Matthew Bowen, sold 13 shares on Oct 5. 30 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
GLUE is #246 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 246 |
Expected to report Tue Mar 16, before the open (in 115 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase was primarily driven by recognition of collaboration revenue from the $50.0 million milestone triggered by the initiation of the Novartis Phase 2 study of MRT-6160 (DDY391) in participants with Sjögren's disease.”
GLUE's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The decrease of $43.4 million was primarily due to operational use of cash.”
From its results filing (SEC filing · Nov 5)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | -3.1% | -5.3% | -4.7% |
| Aug 6, 2026 | +0.1% | +0.6% | +2.2% |
| May 7, 2026 | -0.7% | -2.8% | -7.0% |
Sales grew every year from 2023 to 2025, to $124M. It lost money in each of the three years.
RSI 27.2, MACD below signal, below both averages. Not scored.
3 insiders sold $451K across 3 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: GLUE is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
“The biotechnology industry is extremely competitive in the race to develop new products and the industry is characterized by a high level of innovation and strong emphasis on proprietary products and intellectual property rights.”
GLUE scores -8 today, which Breakaway calls Poor. It is #246 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 5% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%. Shares: 23.5% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
GLUE scores -8 today, which Breakaway calls Poor (below zero). That is #246 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GLUE's -8.
3 insiders sold $451K across 3 filings in the last 6 months. No open-market buys on record. The newest is Matthew Bowen, Principal Accounting Officer, who sold $137.28 on Oct 5. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.